Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Nonadherence to antihypertensive treatment is one of the main causes of the lack of blood pressure (BP) control. The coronavirus disease (COVID-19) pandemic imposes substantial social restriction impairing the medical care routine, which may influence adherence to the antihypertensive treatment. To assess the rate of nonadherence to antihypertensive drug treatment during the COVID-19 pandemic. Methods: This is a cross-sectional study evaluating hypertensive adult patients from a tertiary outpatient clinic. From March to August 2020, patients were interviewed by telephone during the social distancing period of the COVID-19 pandemic. We evaluated biosocial data, habits, attitudes, and treatment adherence using the 4-item Morisky Green Levine Scale during the social distancing. Uncontrolled BP was defined by BP ≥ 140/90 mmHg. Clinical and prescription variables for drug treatment were obtained from the electronic medical record. We performed a multivariate analysis to determine the predictors of nonadherence to BP treatment. Results: We studied 281 patients (age 66 ± 14 years, 60.5% white, 62.3% women, mean education of 9.0 ± 4 years of study). We found that 41.3% of the individuals reported poor adherence to antihypertensive drug treatment and 48.4% had uncontrolled BP. Subsample data identified that adherence was worse during the pandemic than in the previous period. The variables that were independently associated with the nonadherence during the pandemic period were black skin color (odds ratio [OR], 2.62; 95% confidence interval [CI], 1.46-4.68), and intermittent lack of access to antihypertensive medication during the pandemic (OR, 2.56; 95% CI, 1.11-5.89). Conclusions: Beyond traditional variables associated with poor adherence, the lack of availability of antihypertensive medications during the study underscore the potential role of pandemic on hypertension burden.
Abstract
Background: Nonadherence to antihypertensive treatment is one of the main causes of the lack of blood pressure (BP) control. The coronavirus disease (COVID-19) pandemic imposes substantial social restriction impairing the medical care routine, which may influence adherence to the antihypertensive treatment. To assess the rate of nonadherence to antihypertensive drug treatment during the COVID-19 pandemic. Methods: This is a cross-sectional study evaluating hypertensive adult patients from a tertiary outpatient clinic. From March to August 2020, patients were interviewed by telephone during the social distancing period of the COVID-19 pandemic. We evaluated biosocial data, habits, attitudes, and treatment adherence using the 4-item Morisky Green Levine Scale during the social distancing. Uncontrolled BP was defined by BP ≥ 140/90 mmHg. Clinical and prescription variables for drug treatment were obtained from the electronic medical record. We performed a multivariate analysis to determine the predictors of nonadherence to BP treatment. Results: We studied 281 patients (age 66 ± 14 years, 60.5% white, 62.3% women, mean education of 9.0 ± 4 years of study). We found that 41.3% of the individuals reported poor adherence to antihypertensive drug treatment and 48.4% had uncontrolled BP. Subsample data identified that adherence was worse during the pandemic than in the previous period. The variables that were independently associated with the nonadherence during the pandemic period were black skin color (odds ratio [OR], 2.62; 95% confidence interval [CI], 1.46-4.68), and intermittent lack of access to antihypertensive medication during the pandemic (OR, 2.56; 95% CI, 1.11-5.89). Conclusions: Beyond traditional variables associated with poor adherence, the lack of availability of antihypertensive medications during the study underscore the potential role of pandemic on hypertension burden.
참고문헌 (43)
- Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
- "WHO Director-General’s opening remarks at the media briefing on COVID-19: 11 March 2020" (2020)[URL]
- Chakraborty I, "COVID-19 outbreak : migration, effects on society, global environment and prevention", Sci Total Environ, 728, pp.138882~ (2020)
- Skegg D, "Future scenarios for the COVID-19 pandemic", Lancet, 397, pp.777~778 (2021)
- "Coronavirus pandemic" (2020)[URL]
- Lippi G, "Hypertension in patients with coronavirus disease 2019(COVID-19) : a pooled analysis", Pol Arch Intern Med, 130, pp.304~309 (2020)
- Fang L, "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?", Lancet Respir Med, 8, pp.e21~ (2020)
- Pranata R, "Hypertension is associated with increased mortality and severity of disease in COVID-19pneumonia : a systematic review, meta-analysis and meta-regression", J Renin Angiotensin Aldosterone Syst, 21, pp.1470320320926899~ (2020)
- Drager LF, "Is hypertension a real risk factor for poor prognosis in the COVID-19 pandemic?", Curr Hypertens Rep, 22, pp.43~ (2020)
- Ran J, "Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan", China Hypertens Res, 43, pp.1267~1276 (2020)
- Azevedo RB, "COVID-19 and the cardiovascular system : a comprehensive review", J Hum Hypertens, 35, pp.4~11 (2021)
- Gao C, "Association of hypertension and antihypertensive treatment with COVID-19 mortality : a retrospective observational study", Eur Heart J, 41, pp.2058~2066 (2020)
- Clark CE, "COVID-19 and hypertension : risks and management : a scientific statement on behalf of the British and Irish Hypertension Society", J Hum Hypertens, 35, pp.304~307 (2021)
- Brey Z, "Home delivery of medication during coronavirus disease 2019, Cape Town, South Africa : short report", Afr J Prim Health Care Fam Med, 12, pp.e1~e4 (2020)
- Tajeu GS, "Cost-related antihypertensive medication nonadherence : action in the time of COVID-19 and beyond", Am J Hypertens, 33, pp.816~818 (2020)
- Williams B, "2018 ESC", ESH Guidelines for the management of arterial hypertension : the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension : the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension, 2018, pp.36, 1953~2041
- Whelton PK, "The 2017 clinical practice guideline for high blood pressure", JAMA, 318, pp.2073~2074 (2017)
- Izeogu C, "Strategies to improve adherence to anti-hypertensive medications : a narrative review", Curr Hypertens Rep, 22, pp.105~ (2020)
- Coelho JC, "Blood pressure control of hypertensive patients followed in a high complexity clinic and associated variables", J Bras Nefrol, 43, pp.207~216 (2021)
- Morisky DE, "Concurrent and predictive validity of a self-reported measure of medication adherence", Med Care, 24, pp.67~74 (1986)
- Uchmanowicz B, "Selfreported medication adherence measured with Morisky Medication Adherence Scales and its determinants in hypertensive patients aged ≥60 years : a systematic review and meta-analysis", Front Pharmacol, 10, pp.168~ (2019)
- Nielsen JØ, "Non-adherence to anti-hypertensive medication in low-and middle-income countries : a systematic review and meta-analysis of 92443 subjects", J Hum Hypertens, 31, pp.14~21 (2017)
- Schneider AP, "Effect of characteristics of pharmacotherapy on non-adherence in chronic cardiovascular disease : a systematic review and meta-analysis of observational studies", Int J Clin Pract, 72, pp.e13044~ (2018)
- Lemstra M, "Proportion and risk indicators of nonadherence to antihypertensive therapy : a meta-analysis", Patient Prefer Adherence, 8, pp.211~218 (2014)
- Guimarães MCDLP, "Blood Pressure Control and Adherence to Drug Treatment in Patients with Hypertension Treated at a Specialized Outpatient Clinic : A Cross-Sectional Study", Patient Prefer Adherence, 15, pp.2749~2761 (2021)
- Pierin AM, "Hypertension control and related factors at primary care located in the west side of the city of São Paulo", Brazil Cien Saude Colet, 16(Suppl 1), pp.1389~1400 (2011)
- Khan MU, "Barriers to and determinants of medication adherence among hypertensive patients attended National Health Service Hospital", Sunderland J Pharm Bioallied Sci, 6, pp.104~108 (2014)
- Muela HC, "Hypertension severity is associated with impaired cognitive performance", J Am Heart Assoc, 6, pp.e004579~ (2017)
- Abegaz TM, "Nonadherence to antihypertensive drugs : a systematic review and metaanalysis", Medicine(Baltimore), 96, pp.e5641~ (2017)
- Carvalho AS, "Medication adherence in patients with arterial hypertension : the relationship with healthcare systems’ organizational factors", Patient Prefer Adherence, 13, pp.1761~1774 (2019)
- Unger T, "2020 International Society of Hypertension global hypertension practice guidelines", J Hypertens, 38, pp.982~1004 (2020)
- Barroso WK, "Brazilian Guidelines of Hypertension-2020", Arq Bras Cardiol, 116, pp.516~658 (2021)
- Judd SE, "Self-report of stroke, transient ischemic attack, or stroke symptoms and risk of future stroke in the REasons for Geographic And Racial Differences in Stroke(REGARDS)study", Stroke, 44, pp.55~60 (2013)
- Nadruz W Jr, "Racial disparities in risks of stroke", N Engl J Med, 376, pp.2089~2090 (2017)
- Malta DC, "Brazilian lifestyles : national health survey results, 2013", Epidemiol Serv Saúde, 24, pp.217~226 (2015)
- Lackland DT, "Racial differences in hypertension : implications for high blood pressure management", Am J Med Sci, 348, pp.135~138 (2014)
- Macquart de Terline D, "Factors associated with poor adherence to medication among hypertensive patients in twelve low and middle income Sub-Saharan countries", PLoS One, 14, pp.e0219266~ (2019)
- Emmanuel Awucha N, "Impact of the COVID-19pandemic on consumers’ access to essential medicines in Nigeria", Am J Trop Med Hyg, 103, pp.1630~1634 (2020)
- World Health Organization, "Adherence to long-term therapies: evidence for action", pp.196~ (2003), World Health Organization
- Dhar L, "A systematic review of factors influencing medication adherence to hypertension treatment in developing countries", Open J Epidemiol, 7, pp.211~250 (2017)
- Naderi SH, "Adherence to drugs that prevent cardiovascular disease : meta-analysis on 376, 162 patients", Am J Med, 125, pp.882~887 (2012)
- Huang S, "COVID-19 patients with hypertension have more severe disease : a multicenter retrospective observational study", Hypertens Res, 43, pp.824~831 (2020)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan", China Lancet, 395, pp.497~506 (2020)